$ITP

Top 3 Materials Stocks That Could Blast Off This Month - IT Tech Packaging (AMEX:ITP), Ascent Industries (NASDAQ:ACNT)

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.

Original reporting
Benzinga · Avi Kapoor
Published May 14, 2025, 11:22 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 14, 2025, 11:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ITP
Neutral
medium confidence
Mentioned
$ITP · $ACNT
Relevance
6/10
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$ITPNeutralMed
01

Why it matters

The focus on oversold stocks indicates a possible technical rebound, but fundamental analysis is necessary for confirmation.

02

Market read

The news emphasizes technical signals in specific stocks, relevant for traders seeking short-term opportunities in the materials sector.

03

What to watch

Broader macroeconomic factors and sector-specific headwinds could suppress upward movement despite technical signals.

Relevance 6/10Timing: short-term (next 2-4 weeks)

Background

The article highlights undervalued stocks in the materials sector based on technical indicators like RSI, suggesting potential short-term gains.

Company-level read

Ticker impact

$ITPNeutralMedium confidence
Context

Focus on materials sector stocks with potential for growth based on recent oversold conditions.

Expected impact

Moderate upward price correction expected within the next 2-4 weeks.

Evidence & confidence

Technical indicators show oversold conditions, but lack of recent fundamental catalysts limits high confidence.

$ACNTNeutralLow confidence
Context

Ascent Industries (NASDAQ:ACNT) has a neutral sentiment with minimal relevance to current market movements.

Expected impact

Likely sideways trading with minor fluctuations.

Evidence & confidence

Relevance score is low (0.324), indicating limited impact on broader market movements.

Market effects

Potential rebound in materials sector stocks could positively influence related industries such as packaging and industrial materials.

Limited regional impact; primarily US-focused due to stock listings.

Minimal global relevance; sector-specific movement.

Counterpoint

The oversold condition may be a sign of underlying fundamental issues, and a rebound might be limited or short-lived.

Key entities

  • IT Tech Packaging

    A packaging materials company listed on AMEX.

  • Avi Kapoor

    Financial journalist and analyst.

Related articles

$ACNTMedAI 8/10

Ascent Industries (ACNT) Q2 2026 Earnings Call Transcript

Ascent Industries (ACNT) reported Q2 2026 net sales of $25.7 million, up 37.6% year over year, and adjusted EBITDA of $1.5 million versus a prior-year loss. Volume rose 15.2% and average selling prices rose about 23%. Liquidity was $46 million. The Midwest Graphic Sales acquisition added $1.9 million in sales and $300,000 adjusted EBITDA.

$ACNTMed

Ascent Industries Reports Second Quarter 2026 Results; Year-Over-Year Net Sales Increase 37.6% and Adjusted EBITDA Improves by $1.8 Million

ASCENT INDUSTRIES CO. (ACNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ascent Industries Reports Second Quarter 2026 Results; Year-Over-Year Net Sales Increase 37.6% and Adjusted EBITDA Improves by $1.8 Million Sequentially, legacy net sales increased approximately 22% and gross margin expanded approximately 710 basis points; Midwest Gr

$ACNTMed

Ascent Industries Pitches Pure-Play Chemicals Shift, Buybacks and Growth Runway

Ascent Industries (NASDAQ:ACNT) said it is intentionally shifting revenue from custom manufacturing toward product sales, which it expects to be more predictable and margin accretive. Product sales rose from ~10% of sales in 2023 to ~27% in 2024 and ~30% last year. Management cited $7M and $10M net-new business from recent customer wins, underutilized assets (~45% utilization), and a $14M Midwest Graphic Sales acquisition (closed early May) with $10.8M revenue and ~$2M adjusted EBITDA.

$GMABHigh

Genmab’s petosemtamab trial cuts death risk by 50% in cancer

Genmab A/S (GMAB) reported that its Phase 3 trial for petosemtamab met primary endpoints, reducing death risk by 50% in head and neck cancer patients. The combination therapy showed significant improvements in overall survival and response rates, with a hazard ratio of 0.50 and an objective response rate odds ratio of 3.17. The company plans regulatory submissions and further trial evaluations. Head and neck squamous cell carcinoma is the seventh most common cancer globally.

$MLYSMedAI 8/10

Mineralys Reports Phase 2 Lorundrostat Data In Chronic Kidney Disease

Mineralys Therapeutics (MLYS) reported Phase 2 trial results for Lorundrostat in chronic kidney disease patients, showing significant blood pressure reduction and kidney damage markers improvement. The drug is being evaluated for high blood pressure and related conditions. MLYS stock is currently at $21.09, down 0.21%.